Phase II trial of KW2189 in patients with advanced malignant melanoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 3, 2002, Pages 308-312

  Markovic, Svetomir N ^a   Suman, Vera J ^a   Vukov, Allen M ^a   Fitch, Tom R ^a   Hillman, David W ^a   Adjei, Alex A ^a   Alberts, Steven R ^a   Kaur, Judith S ^a   Braich, Theodore A ^a   Leitch, John M ^a   Creagan, Edward T ^a  

^a MAYO CLINIC   (United States)

Author keywords

Clinical trial; KW2189; Melanoma; Stage IV

Indexed keywords

PIBROZELESIN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MELANOMA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; HUMANS; MELANOMA; PYRROLIDINONES; SURVIVAL RATE;

EID: 0036269229     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200206000-00022     Document Type: Article

References (24)

1. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: A summary of 84,836 cases from the past decade
2. Duocarmycins, potent antitumor antibiotics produced by Streptomyces sp. structures and chemistry
3. Structure of duocarmycin SA, a potent antitumor antibiotic
4. Structures of duocarmycins, novel antitumor antibiotics produced by Streptomyces sp
5. Sequence-specific alkylation of DNA by duocarmycin A, and its novel derivatives bearing PY/IM polyamides
6. Concerted DNA recognition and novel site-specific alkylation by duocarmycin A with distamycin A
7. Site specific covalent alkylation of DNA by antitumor antibiotics, duocarmycin A and kapurimycin A3
8. Duocarmycin A, a new antitumor antibiotic from Streptomyces
9. Differential effect of duocarmycin A and its novel derivative DU-86 on DNA strand breaks in HeLa S3 cells
10. Anticellular and antitumor activity of duocarmycins, novel antitumor antibiotics
11. Duocarmycin SA, a new antitumor antibiotic from Streptomyces sp
12. Interconversion and stability of duocarmycins, a new family of antitumor antibiotics: Correlation to their cytotoxic and antimicrobial activities in vitro
13. Synthesis and antitumor activity of water-soluble duocarmycin B1 prodrugs
14. A novel antitumor antibiotic, KW-2189 is activated by carboxyl esterase and induces DNA strand breaks in human small cell lung cancer cells
15. Synthesis and antitumor activity of duocarmycin derivatives: Modification of segment A of duocarmycin B2
16. Synthesis and antitumor activity of duocarmycin derivatives: A-ring pyrrole analogues of duocarmycin B2
17. Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors
18. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks
19. Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11
20. In vitro enhancement of antitumor activity of a water-soluble duocarmycin derivative, KW-2189, by caffeine-mediated DNA-repair inhibition in human lung cancer cells
21. Novel cyclopropapyrroloindole derivative (AT-3510) bearing methoxycarbonyl and trifluoromethyl groups
22. New water-soluble duocarmycin derivatives: Synthesis and antitumor activity of A-ring pyrrole compounds bearing beta-heteroarylacryloyl groups
23. Synthesis and antitumor activity of duocarmycin derivatives: Modification of segment-A of A-ring pyrrole compounds
24. Synthesis and antitumor activity ofduocarmycin derivatives: A-ring pyrrole compounds bearing 5-membered heteroarylacryloyl groups